ESR1 and breast carcinoma: Moreover, TAM and its metabolite, 4-hydroxy-tamoxifen, both of which are known antagonists of ERα, were demonstrated to function as agonists of GPR30 and promote the proliferation and migration in breast cancer cell lines [14].